LifeScience Biologics
METiS TechBio’s AI-Designed MTS-004 Meets Phase III Success in China, Targeting Pseudobulbar Affect
MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) METiS TechBio, a global leader in AI-driven nanodelivery and formulatio...
October 24, 2025 | News
AGC Biologics Partners With Rarity PBC To Advance First U.S. Commercial Gene Therapy for ADA-SCID
Collaboration will leverage AGC Biologics’ commercial manufacturing experience and proven platforms to seek regulatory approval for a therapy treat...
October 24, 2025 | News
Teijin Pharma Licenses Rheumatoid Arthritis Drug Candidate TCK-276 to UK-Based Elevara Medicines in Global Agreement
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, announced that has entered into an exclusive ...
October 24, 2025 | News
BioMed X and Daiichi Sankyo Launch New Research Team in Heidelberg to Advance Multispecific Biologics for Solid Tumour Immunotherapy
BioMed X, a leading innovation hub for pharma,announced the start of a new research team at its Heidelberg institute for multispecific biologics in th...
October 24, 2025 | News
Syngene Strengthens India’s ADC Ecosystem With New GMP Bioconjugation Suite in Bengaluru
Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commerci...
October 24, 2025 | News
ACM Biolabs and National Cancer Centre Singapore Report Encouraging Asia-Based Early Clinical Findings for ACM-CpG Nanoparticle Immunotherapy
ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, announced encouraging early clinica...
October 23, 2025 | News
Takeda and Innovent Biologics Announce Global Collaboration for Two Late-Stage Oncology Programs Valued at Over US$1.2 Billion
Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to Li...
October 23, 2025 | News
Cambrex Announces $120 Million U.S. Expansion to Strengthen API Manufacturing and Peptide Therapeutics Capabilities
Cambrex, a leading global contract development and manufacturing organization (CDMO), announced a $120 million investment to expand i...
October 23, 2025 | News
Forlong Biotechnology and Henlius Join Forces to Develop Targeted Cytokine-Based Cancer Immunotherapy
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, toda...
October 23, 2025 | News
SunRock Biopharma and Chime Biologics Partner to Advance Novel Anti-CCR9 Antibody Therapy for Inflammatory Bowel Disease
SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contrac...
October 22, 2025 | News
AdvanCell’s Lead-212 Radioligand Therapy Shows Strong Safety and Efficacy in Phase 1b Trial for Metastatic Prostate Cancer
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastat...
October 22, 2025 | News
Samsung Bioepis and Phrontline Partner to Develop Next-Generation Bispecific, Dual-Payload ADC Therapies for Solid Tumours
Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against targets expressed in a broad r...
October 22, 2025 | News
Alphamab Oncology and CSPC’s HER2-Targeting ADC JSKN003 Receives Breakthrough Therapy Designation in China for Advanced Colorectal Cancer
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targ...
October 21, 2025 | News
Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced that it has successfully completed the acquisition of Prothya Biosolutions ...
October 21, 2025 | News
Most Read
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
